Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2000
11/23/2000WO2000069810A1 Glucagon antagonists/inverse agonists
11/23/2000WO2000069515A1 Remote and local controlled delivery of pharmaceutical compounds using electromagnetic energy
11/23/2000WO2000069472A2 Enzyme-activated anti-tumor prodrug compounds
11/23/2000WO2000069468A1 Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
11/23/2000WO2000069467A1 Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
11/23/2000WO2000069459A1 Treatment of refractory human tumors with epidermal growth factor receptor antagonists
11/23/2000WO2000069434A1 Dfmo and celecoxib in combination for cancer chemoprevention and therapy
11/23/2000WO2000069425A2 Endoparasiticidal synergistic combination containing cyclic depsipeptides and piperazines
11/23/2000WO2000069424A2 Method of treating psychotic disorders
11/23/2000WO2000069255A1 Anti-inflammatory therapy for inflammatory mediated infection
11/23/2000WO2000038706A3 Methods for treating cancer and for mediating chemotaxis of dendritic cells
11/23/2000WO2000037502A3 Vascular endothelial cell growth factor antagonists and uses thereof
11/23/2000WO2000036918A9 Methods and compositions for treatment of cell proliferative disorders
11/23/2000WO2000036090A3 Human brain endothelial cells and growth medium and method for expansion of primitive cd34+cd38- bone marrow stem cells
11/23/2000WO2000034295A3 Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
11/23/2000WO2000032267A3 Device for locally delivering a drug in a body cavity
11/23/2000WO2000031242A3 Engineered cytotoxic ribonuclease
11/23/2000WO2000031124A3 Peptides that modulate the interaction of b class ephrins and pdz domains
11/23/2000WO2000031100A3 Benzylmaltosides as inhibitors of smooth muscle cell proliferation
11/23/2000WO2000028020A3 Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
11/23/2000WO2000027194A9 Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
11/23/2000WO2000026348A3 Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity
11/23/2000WO2000016764A3 Pharmaceutical compositions comprising derivatives of sulphur acids
11/23/2000WO2000012740A3 Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences
11/23/2000WO2000007545A3 Apoptosis proteins
11/23/2000WO2000004863A3 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
11/23/2000WO1999048482A3 Smilagenin and anzurogenin-d for the treatment of alzheimer's disease
11/23/2000WO1999045952A3 Method of preventing the death of retinal neurons and treating ocular diseases
11/23/2000WO1999004775A3 Method of treating dopaminergic and gaba-nergic disorders
11/23/2000DE19922462A1 New phenylureidobenzyl-substituted spiro-imidazolidinedione derivatives, are inhibitors of leukocyte adhesion or migration or VLA-4 receptors, useful e.g. for treating inflammatory or allergic disease
11/23/2000DE19919634A1 Test zur Bestimmung der Integrität komplexer Phospholipid/Lipid-Strukturen mit Hilfe synthetischer NBD-markierter Acylglyceride und dessen Anwendung zur Bestimmung der Aktivität von Lipasen Test to determine the integrity of complex phospholipid / lipid structures using synthetic NBD-labeled acylglycerides and its application to determination of the activity of lipases
11/23/2000CA2623458A1 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
11/23/2000CA2505617A1 Modified secretin and method of synthesizing thereof
11/23/2000CA2499211A1 Modified peptides yy and conjugates thereof
11/23/2000CA2374559A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
11/23/2000CA2374297A1 Furanone derivatives as inhibitors of cathepsin s
11/23/2000CA2374045A1 Compositions isolated from skin cells and methods for their use
11/23/2000CA2373931A1 Dfmo and celecoxib in combination for cancer chemoprevention and therapy
11/23/2000CA2373892A1 Glucagon antagonists/inverse agonists
11/23/2000CA2373855A1 Method of treating psychotic disorders
11/23/2000CA2373815A1 Treatment of refractory human tumors with epidermal growth factor receptor antagonists
11/23/2000CA2373666A1 Benzofuranylsulfonates
11/23/2000CA2373614A1 Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants
11/23/2000CA2373610A1 Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
11/23/2000CA2373607A1 Cyclic amine derivatives and their uses
11/23/2000CA2373509A1 Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
11/23/2000CA2373500A1 Hydroxamic acid derivatives as matrix metalloprotease inhibitors
11/23/2000CA2373439A1 Novel hydroxamic acid derivatives
11/23/2000CA2373231A1 Extracellular signaling molecules
11/23/2000CA2372934A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
11/23/2000CA2372926A1 143 human secreted proteins
11/23/2000CA2372919A1 Remote and local controlled delivery of pharmaceutical compounds using electromagnetic energy
11/23/2000CA2372617A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
11/23/2000CA2372541A1 Sphingosine kinase enzyme
11/23/2000CA2372534A1 Differentiated human embryoid cells and a method for producing them
11/23/2000CA2372494A1 Compounds having cytokine inhibitory activity
11/23/2000CA2372429A1 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
11/23/2000CA2372426A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/23/2000CA2372304A1 Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins
11/23/2000CA2372119A1 Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily
11/23/2000CA2372068A1 Sulphostin analogue and process for producing sulphostin and its analogue
11/23/2000CA2370245A1 Enzyme-activated anti-tumor prodrug compounds
11/23/2000CA2369376A1 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer and for prevention of cancer in at-risk subjects
11/23/2000CA2368624A1 Novel .beta.-secretase and modulation of .beta.-secretase activity
11/23/2000CA2368593A1 Anti-inflammatory therapy for inflammatory mediated infection
11/22/2000EP1054064A1 Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
11/22/2000EP1054017A1 Salts of thrombin inhibitors
11/22/2000EP1053750A1 Use of proteasome-inhibitor for the induction of programmed cell death (apoptosis)
11/22/2000EP1053748A1 Remedies for neurological disorders
11/22/2000EP1053356A2 Method for diagnosis and treatment of disorders of carbohydrate metabolism
11/22/2000EP1053324A1 Novel cystine knot protein and materials and methods for making it
11/22/2000EP1053321A1 Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
11/22/2000EP1053320A2 Human transport-associated molecules
11/22/2000EP1053316A1 Nucleic acids provided for modulating cellular activation
11/22/2000EP1053308A1 Dendritic enriched secreted lymphocyte activation molecule
11/22/2000EP1053307A1 Podocalyxin like sialomucins having selectin ligand activity
11/22/2000EP1053255A1 THREE-DIMENSIONAL STRUCTURES AND MODELS OF Fc RECEPTORS AND USES THEREOF
11/22/2000EP1053247A1 Antifungal cyclohexapeptides
11/22/2000EP1053246A1 Beta-sheet mimetics and methods relating to the use thereof
11/22/2000EP1053241A1 Novel dimerizing agents, their production and use
11/22/2000EP1053240A1 Glucocorticoid-selective antiinflammatory agents
11/22/2000EP1053236A1 Pyrdiyl-briidgehead derivatives and their analogues, pharmaceutical compositions and their use as inhibitors of nicotinic cholinergic receptors
11/22/2000EP1053235A1 Oxazole derivatives as serotonin-1a receptor agonists
11/22/2000EP1053233A1 Hydroxamic and carboxylic acid derivatives
11/22/2000EP1053227A1 Ppar-gamma modulators
11/22/2000EP1053226A1 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
11/22/2000EP1053224A1 Biphenylsulfonyl cyanamides, method for the production thereof and their utilization as a medicament
11/22/2000EP1053022A2 Sensitizing cells to compounds using lipid-mediated gene and compound delivery
11/22/2000EP1053020A1 Absorbable microparticles
11/22/2000EP1053013A1 Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob
11/22/2000EP1053010A1 Copolymer compositions for oral delivery
11/22/2000EP1053009A2 Use of heregulin as an epithelial cell growth factor
11/22/2000EP1053007A2 Methods and compositions for modulating leptin activity
11/22/2000EP1053006A1 Costimulatory blockade and mixed chimerism in transplantation
11/22/2000EP1052998A1 Compositions and methods for modulating cytokine release in response to genotoxic agents
11/22/2000EP1052996A1 Medicine for treating apoptosis dysfunction containing oligosaccharides
11/22/2000EP1052994A2 Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
11/22/2000EP1052992A1 Cyclic amine modulators of chemokine receptor activity
11/22/2000EP1052989A1 Use of 2-amino-6- trifluoromehthoxy- benzothiazole for preventing or treating cerebellum dysfunction
11/22/2000EP1052985A1 Pharmaceuticals comprising n,n'-bis(2-hydroxybenzyl)ethylenediamine-n,n'-diacetic acid for iron chelating therapy
1 ... 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 ... 1564